27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Dementia is a growing global concern, with informal caregivers, typically unpaid family members or friends, providing essential support to those living with the condition. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Mercury remains a pervasive environmental neurotoxicant strongly implicated in hippocampal oxidative injury and dementia-related cognitive decline, yet safe multi-target agents against its neurotoxicity remain limited. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Findingss: uggested that dementia reshaped the structure and intensity of the shared decision-making process by increasing surrogate engagement and decisional demands, underscoring the importance of early advance care planning and structured support for family caregivers to sustain goal-concordant care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This study reveals a critical disconnect between moderate dementia knowledge and the application of this knowledge into perceived clinical competence. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
STRUCTURED ABSTRACT INTRODUCTION The Dementia DataHub (DDH) reports U.S. dementia prevalence and incidence from Medicare data. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Medicare Part D drug spending was substantial, increasing with dual-eligibility duration: $8732-$9107 among beneficiaries with full-year dual eligibility and exceeding $11 500 among those with 5+ chronic conditions. 1 key finding →
Design: cross-sectional Participants: 1,372,696 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Among 421,131 MA beneficiaries, telehealth use increased sharply in Q2 2020 for both ADRD and non-ADRD groups, peaking at 33.9 and 30.6% respectively. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Central-northern rural communities exhibited the most pronounced high-high spatial clustering of cognitive impairment (Global Moran's I = 0.17, p < 0.001). 5 key findings →
Design: cross-sectional Participants: 18,963 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of treatment response. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Systemic inflammatory biomarkers were primarily associated with age/socio-demographic characteristics, remained strikingly stable over time, and were not associated with AD progression. 5 key findings →
Participants: 333 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.032). In individuals with LOUE, elevated plasma p-tau217 was associated with both cognitive impairment and disrupted sleep microarchitecture, with the most pronounced cognitive deficits observed in individuals with medication refractory epilepsy. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Non-core NfL and GFAP biomarkers are associated with both cross-sectional and longitudinal cognitive performance. 5 key findings →
Design: cross-sectional Participants: 334 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundSystemic inflammation has been implicated in cognitive aging and neurodegeneration; however, inflammatory biomarkers are expressed in coordinated patterns rather than as isolated markers. 4 key findings →
Design: cross-sectional Participants: 334 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Among most Latinos in northern Manhattan who learned they had an APOE ε4/ε4 genotype, disclosure did not provoke elevated levels of distress. 3 key findings →
Participants: 61 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
= 0.036), with lower scores in PCA and lvPPA (median 21 and 21, respectively) compared with CBS-AD (median 27). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Anti-amyloid monoclonal antibody therapies (AATs) are increasingly used for the treatment of early symptomatic Alzheimer disease. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) is a progressive brain disorder that leads to memory loss and a gradual decline in thinking and reasoning abilities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
At baseline, nearly one-third of caregivers reported moderate-to-severe burden (mean ZBI 31.4 ± 15.4), a prevalence that persisted at 6 months. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A significant association between increased caregiver burden and BPSD in patients with AD was demonstrated, which may be associated with decreased caregiver healthcare and social care-related QOL. 2 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The caregivers in intervention group showed significant reductions in distress scores for dressing, personal hygiene, communication, and behavioural and psychological care problems at both the 6th and 12th week assessments. 5 key findings →
Participants: 125 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
With the increased use of technological supports in residential care homes, there is growing interest in the use of real-time location systems (RTLS) to enhance safety and streamline care. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Black caregivers reported shorter sleep duration but lower daily pain than White caregivers. 5 key findings →
Participants: 210 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of the n = 180 participants recruited, n = 77 participated in this study, n = 37 caregivers and n = 40 non-caregivers. 5 key findings →
Participants: 180 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We found comparable associations between dementia and PRS when comparing a C+T method with only 15 SNPs and PRS derived from Bayesian models that include > 800,000 SNPs (HR 5e‐08 = 1.18, 95% CI: 1.08–1.28; HR CSx = 1.17, 95% CI: 1.07−1.27). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identifying older adults at increased dementia risk is a public health priority. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →